Enanta Pharmaceuticals (ENTA) Cash from Operations (2012 - 2026)

Enanta Pharmaceuticals has reported Cash from Operations for 15 years, with the latest figure at 7156000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 46.95% year-over-year to 7156000.0; the trailing twelve-month figure through Mar 2026 stood at 7838000.0 (up 85.87% YoY), and the FY2025 full-year result was 19272000.0, up 75.53% from the prior year.
• Cash from Operations for Q1 2026 stood at 7156000.0, up from 11699000.0 in the prior quarter.
• The five-year high for Cash from Operations was 17506000.0 in Q2 2025, with the low at 35641000.0 in Q4 2022.
• Historically, Cash from Operations has averaged 17150352.94 across 5 years, with a median of 15534000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 476.0% — and 2025, when it surged 218.48%.
• Enanta Pharmaceuticals' Cash from Operations stood at 35641000.0 in 2022, then rose by 29.89% to 24988000.0 in 2023, then jumped by 32.76% to 16801000.0 in 2024, then soared by 30.37% to 11699000.0 in 2025, then surged by 38.83% to 7156000.0 in 2026.
• The last three Cash from Operations figures came in at 7156000.0 (Q1 2026), 11699000.0 (Q4 2025), and 6489000.0 (Q3 2025), per Business Quant data.